| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 05/13/2004 | WO2004039378A1 Preparations comprising 1,3 and/or 1,6 beta glucans for the treatment of infections and inflammations in animals |
| 05/13/2004 | WO2004039377A1 Use of piperazine sulfonic acid derivatives as ccr1 antagonists for the treatment of fibrosis, alzheimer disease and other disorders |
| 05/13/2004 | WO2004039234A2 Humanized antibodies against the venezuelan equine encephalitis virus |
| 05/13/2004 | WO2004029066A8 Bifunctional heterocyclic compounds and methods of making and using same |
| 05/13/2004 | WO2004024078A3 Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors |
| 05/13/2004 | WO2004017950A3 Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| 05/13/2004 | WO2004005293A3 N-aryl diazaspiracyclic compounds and methods of preparation and use thereof |
| 05/13/2004 | WO2003106461A3 Pseudopolymorphic forms of a hiv protease inhibitor |
| 05/13/2004 | WO2003089472A3 Anti-nls scfv and peptides and uses thereof in nuclear import inhibition |
| 05/13/2004 | WO2003079750A3 ANTAGONISTIC ANTI-hFAS LIGAND HUMAN ANTIBODIES AND FRAGMENTS THEREOF |
| 05/13/2004 | WO2003077830A3 9-dexo-9a-aza-9a-methyl-9a-homoerythromycin a derivatives |
| 05/13/2004 | WO2003070190A3 Surrogate antibodies and methods of preparation and use thereof |
| 05/13/2004 | WO2003051454A3 Methods for particle-assisted polynucleotide immunization using a pulsed electric field |
| 05/13/2004 | WO2003049762A3 Immunisation against chlamydia trachomatis |
| 05/13/2004 | WO2003034903B1 Psma antibodies and protein multimers |
| 05/13/2004 | WO2003033657A3 Antisense antiviral agent and method for treating ssrna viral infection |
| 05/13/2004 | WO2002085447A8 Microprojection array having a beneficial agent containing coating |
| 05/13/2004 | WO2002016440A9 Haemophilus influenzae lipopolysaccharide inner-core oligosaccharide epitopes as vaccines for the prevention of haemophilus influenzae infections |
| 05/13/2004 | US20040092911 Ophthalmic drug delivery device |
| 05/13/2004 | US20040092745 Piperidine derivatives useful as CCR5 antagonists |
| 05/13/2004 | US20040092736 Collections of compounds |
| 05/13/2004 | US20040092730 Hepatitis C virus non-structural NS3/4A fusion gene |
| 05/13/2004 | US20040092598 Antiproliferative agnets; anticancer agents; skin disorders |
| 05/13/2004 | US20040092583 Treatment for inhibiting neoplastic lesions |
| 05/13/2004 | US20040092581 Ratjadone derivatives for inhibiting cell growth |
| 05/13/2004 | US20040092575 Prevent insertion of peptide into cell membranes |
| 05/13/2004 | US20040092569 Analgesics, antiinflammatory agents, autoimmune diseases, bone disorders, central nervous system disorders |
| 05/13/2004 | US20040092556 Aids therapy |
| 05/13/2004 | US20040092551 Piperidine derivatives useful as CCR5 antagonists |
| 05/13/2004 | US20040092545 Sulfonamido ether substituted imidazoquinolines |
| 05/13/2004 | US20040092524 Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same |
| 05/13/2004 | US20040092515 Diaminoquinazoline esters for use as dihydrofolate reductase inhibitors |
| 05/13/2004 | US20040092486 Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders |
| 05/13/2004 | US20040092476 Anticancer agents; viricides |
| 05/13/2004 | US20040092459 Novel macrolides |
| 05/13/2004 | US20040092454 3-biphenyl-4-yl-3-(2-(4-(pyridin-2-ylamino)pentanoylamino)-pen tanoyl amino)propionic acid derivatives |
| 05/13/2004 | US20040092444 Neuroprotective synergy of erythropoietin and insulin-like growth factor |
| 05/13/2004 | US20040091964 Modified proteins, isolated novel peptides,and uses thereof |
| 05/13/2004 | US20040091890 Life sciences business systems and methods |
| 05/13/2004 | US20040091878 Zinc finger domain recognition code and uses thereof |
| 05/13/2004 | US20040091852 Glycoprotein peptide of the human herpesvirus-7 for use in particular in an elisa serologic test |
| 05/13/2004 | US20040091555 Methods for producing agrimonia extracts with improved activity against hepatitis b virus and pharmaceutical and food compositions containing said extracts |
| 05/13/2004 | US20040091536 Stability of masking of the taste when the reconstitutable, dry suspension contains granules having a core of drug and excipients (thickener, preservative and buffer) and at least three successive layers of coating; organoleptic |
| 05/13/2004 | US20040091527 Method of increasing the bioavailability and tissue penetration of azithromycin |
| 05/13/2004 | US20040091518 Lysine mixture and apparatus and method for administering lysine |
| 05/13/2004 | US20040091501 Immunosuppresor agent derived from morbillivirus |
| 05/13/2004 | US20040091498 Defensins: use as antiviral agents |
| 05/13/2004 | US20040091493 Active ingredient such as specified plant extract(s) or calcium compound that does not cause any inflammatory, irritation or intolerance reactions; tissue models for drug screening for drugs against skin disorders; dandruff, acne |
| 05/13/2004 | US20040091481 Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes |
| 05/13/2004 | US20040091479 T-cell epitope of the papillomavirus l1 and e7 protein and use thereof in diagnostics and therapy |
| 05/13/2004 | US20040091478 Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding |
| 05/13/2004 | DE20220744U1 Mittel zur Hemmung von Lentiviren Means for inhibiting lentiviruses |
| 05/13/2004 | DE10248453A1 Chalcomycin-Derivate Chalcomycin derivatives |
| 05/13/2004 | CA2504205A1 Angiotensin-converting enzyme containing medecine |
| 05/13/2004 | CA2503946A1 Drying process |
| 05/13/2004 | CA2503693A1 Use of cpg oligonucleotides in the treatment of hepatitis c virus infection |
| 05/13/2004 | CA2500850A1 Use of piperazine sulfonic acid derivatives as ccr1 antagonists for the treatment of fibrosis, alzheimer disease and other disorders |
| 05/13/2004 | CA2500487A1 Hiv-integrase inhibitors, pharmaceutical compositions, and methods for their use |
| 05/13/2004 | CA2498642A1 Composition for the treatment of infection by flaviviridae viruses |
| 05/13/2004 | CA2485342A1 Humanized antibodies against the venezuelan equine encephalitis virus |
| 05/12/2004 | EP1418180A2 Chimeric chains that code for proteins that induce effects directed against viruses |
| 05/12/2004 | EP1418179A2 Compositions and methods for detecting and modulating rna activity and gene expression |
| 05/12/2004 | EP1418177A1 Novel pseudolaric acid-b derivatives, their preparation and pharmaceutical compositions |
| 05/12/2004 | EP1418175A1 Respiratory syncytial virus replication inhibitors |
| 05/12/2004 | EP1418174A2 Amorphous Ritonavir |
| 05/12/2004 | EP1418164A1 New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists |
| 05/12/2004 | EP1417973A2 Vaccine formulation potentiated by the combination of a dna and an antigen |
| 05/12/2004 | EP1417967A1 Novel virus proliferation inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue |
| 05/12/2004 | EP1417966A1 Flavonol glycosides as neutralizing agent for clostridium bacterial neurotoxins and preparation method thereof |
| 05/12/2004 | EP1417328A2 Invasion complex and methods of targeting |
| 05/12/2004 | EP1417236A2 Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| 05/12/2004 | EP1417233A2 Human recombinant antibody against the hepatitis c (hcv) non structural ns3 protein, nucleic acid and uses thereof |
| 05/12/2004 | EP1417231A2 Modified human thymic stromal lymphopoietin |
| 05/12/2004 | EP1417228A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 05/12/2004 | EP1417227A2 Peptides eefective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 05/12/2004 | EP1417222A1 Isolated polypeptides based on the neutralizing epitope of the p17 protein of hiv useful as vaccines, and neutralzing annti-p17 antibodies which specifically recognize said neutralizing epitope |
| 05/12/2004 | EP1417221A2 Mimotope of neisseria meningitidis lipooligosaccharide and vaccines containing the same |
| 05/12/2004 | EP1417202A2 Aminopiperidine derivatives as modulators of chemokine receptor activity |
| 05/12/2004 | EP1417196A1 Dna-pk inhibitors |
| 05/12/2004 | EP1417186A2 Heterocyclic aryl sulphonamides |
| 05/12/2004 | EP1417177A2 Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
| 05/12/2004 | EP1417055A2 Use of copper chelators to inhibit the inactivation of protein c |
| 05/12/2004 | EP1416986A2 Intradermal delivery of vaccines and gene therapeutic agents via microcannula |
| 05/12/2004 | EP1416974A1 Gas microsphere liposome composites |
| 05/12/2004 | EP1416958A1 Vaccine composition comprising at least two valences, one enhanced with adjuvant and not the other |
| 05/12/2004 | EP1416945A1 Improved heteropolymer complexes and methods for their use |
| 05/12/2004 | EP1416941A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
| 05/12/2004 | EP1416940A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine |
| 05/12/2004 | EP1416936A1 Thiopyrane-4-ones as dna protein kinase inhibitors |
| 05/12/2004 | EP1416926A2 Zinc containing compositions for anti-viral use |
| 05/12/2004 | EP1416885A2 Methods and devices for delivery of therapeutic capable agents with variable release profile |
| 05/12/2004 | EP1416884A2 Delivery of therapeutic capable agents |
| 05/12/2004 | EP1416799A1 Methods and compositions for treating fungal infections |
| 05/12/2004 | EP1383464A4 Nail compositions and methods of administering same |
| 05/12/2004 | EP1309352B1 Antifungal ketoconazole composition for topical use |
| 05/12/2004 | EP1303284A4 Compositions and methods for the treatment of skin damage |
| 05/12/2004 | EP1163208B1 Caspase inhibitors and uses thereof |
| 05/12/2004 | EP1112070B1 Novel substituted triazole compounds |
| 05/12/2004 | EP1069898B1 Topical antiseptic compositions and methods |
| 05/12/2004 | EP1058559B1 Combination of a selective nmda nr2b antagonist and a cox-2 inhibitor |